Here is the design of a clinical trial:

Official Title: Mise en Place d'un Plan Pharmaceutique Personnalisé Chez Les Patients transplantés rénaux ou hépatiques : Essai randomisé en Cluster de Type Stepped-wedge.

Included conditions:
- Personalized Pharmaceutical Plan After Transpantation

Study Armgroups:
- {'label': 'Intervention', 'type': 'EXPERIMENTAL', 'description': "Implementation of a personalized pharmaceutical plan with a view to increasing the patient's therapeutic education in the hospital and in the community (entrance and discharge reconciliation, 3 pharmaceutical interviews in the hospital, strengthening of the community-hospital link , 3 outpatient pharmaceutical consultations)", 'interventionNames': ['Behavioral: PPP']}
- {'label': 'Usual care period', 'type': 'NO_INTERVENTION', 'description': 'No changes to usual center practices'}

Interventions:
- {'type': 'BEHAVIORAL', 'name': 'PPP', 'description': 'Personalized Pharmaceutical Plan on therapeutic adherence to immunosuppressive treatments after the transplantation', 'armGroupLabels': ['Intervention']}

Primary Outcomes:
- {'measure': 'Therapeutic adhesion', 'description': 'The Investigator will consider that a patient is in therapeutic adhesion thanks to two methods : use of the BAASIS® questionnaire (if answer \\<1 for at least one of the 4 questions in the score, the patient will be considered as a non-adherent) and use of the health insurance data from the national health data system (checking that 100% of the days are covered by possession of immunosuppressive drugs)', 'timeFrame': '1 year after transplantation'}

Please estimate the sample size based on the assumption: 
The study design is a stepped-wedge with 12 sequences, 14 periods, 11 patients per cluster-period, 90% power, and an intraclass correlation coefficient of 0.01. A 25% exclusion rate is also considered.
Sample size calculation
        Currently, non-adherence to immunosuppressive treatment is approximately 30% [4]. The objective of the intervention is to reduce this percentage by one-third, i.e. to 20%. Considering a stepped-wedge design with 12 sequences (one cluster per sequence) of fourteen 7-week periods (one of which is a transition period), with a mean number of 11 patients recruited per cluster-period, this provides a 90% power to the study, taking into account an intraclass correlation coefficient of 0.01. Consequently, the total number of patients needed is 1716 of whom 132 are expected to be included in a transition period. Sample size calculation has been done using the shiny cluster randomized calculator [10, 11].
        According to the French regulatory Agencyâs 2017 data, the 12 recruited clusters could in turn recruit 2461 patients over 23 months. Considering that 25% of transplanted patients will have at least one exclusion criterion, 1846 patients will be included over 23 months.